



Media Contact: Jeanne A. Becker
Becker Public Relations
Public Relations, Event Planning and Marketing
2506 Ponce de Leon Blvd.
Coral Gables, FL 33134
Telephone 305/444-2181 X 222
Email: jbecker@beckerpublicrelations.com

For Immediate Release

**BIOHEART CONSORTIUM OF DIRECTORS AND
SHAREHOLDERS PURCHASE NOTE SHOWING
CONTINUED CONFIDENCE IN COMPANY'S FUTURE**

Sunrise, FL – March 14, 2012 - Bioheart, Inc. (BHRT.OB) announced today that NorthStar Biotech LLC, a consortium of Bioheart Directors and Shareholders, has purchased a company note in the amount of \$572,000 previously held by BlueCrest Venture Finance Master Fund Limited.

“We have renewed confidence in Bioheart and the commercial viability of their stem cell therapies aimed at improving cardiac function in chronic heart failure patients,” said Chuck Hart, Managing Director of NorthStar Biotech LLC and a Bioheart Director and longtime shareholder. According to Hart, the NorthStar note purchase protects the company’s sought after intellectual property and the preferred position of other shareholders in the company.

-MORE-

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

P:Becker/Bioheart/Press Releases/NorthStar Note Purchase.docx